Dr. Tombal on Darolutamide Monotherapy in Newly Diagnosed mHSPC
Bertrand Tombal, MD, PhD, discusses the rationale for conducting a phase 2 study of darolutamide monotherapy in newly diagnosed metastatic hormone-sensitive prostate cancer.
Dr. Tombal on the OS Benefit of Darolutamide Plus ADT/Docetaxel in mHSPC
Bertrand Tombal, MD, PhD, discusses the overall survival benefit associated with androgen-deprivation therapy plus darolutamide in metastatic hormone-sensitive prostate cancer.
Further Understanding of Immune Mechanisms in Tumor Microenvironment Is Key to Advancing Immunotherapy in Solid Tumors
Navigating Systemic Therapy for RCC: Balancing Risk Status and Response
ADCs, Novel Targets Represent Next Wave of Treatment Advances in mCRPC
Precision Medicine in Prostate Cancer Care: Keeping Up With Evolving Guidance for Testing and Decision Making
2 Clarke Drive Cranbury, NJ 08512